Skip to main content
Premium Trial:

Request an Annual Quote

DiaGenic, Harvard Medical School to Use Michael J. Fox Funds for Parkinson’s Dx Research

NEW YORK (GenomeWeb News) – DiaGenic and researchers at Harvard Medical School will use funding from the Michael J. Fox Foundation to develop a blood-based test for early detection of Parkinson’s disease.
 
DiaGenic will work with Clemens Scherzer, an assistant professor of neurology at Brigham and Women’s Hospital and Harvard Medical School, who has led the MJFF-funded Harvard PD Biomarker Study for three years.
 
The study partners will identify and validate gene expression signatures for Parkinson’s using peripheral blood samples that have already been collected for the Harvard study. Signatures will be incorporated into a test to run on a standard platform that will be combined with DiaGenics’ analysis software.
 
The grant will cover the initial funding for the study, the company said, but the amount of the gift was not disclosed. 
 
Scherzer said in a statement that he is “optimistic that the use of peripheral gene expression will prove valuable for the early detection of neurological disorders.”

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.